| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.710 | GeneticVariation | BEFREE | Here, we show that depletion of RAF-1, a RAF family member with a poorly defined role in TC, decreases proliferation and increases apoptosis in TPC-1 cells and, less significantly, in cells harboring a BRAF(V600E) or HRAS(G13R) mutations, but without affecting ERK activation. | 26265449 | 2015 |
||||
|
G | 0.710 | CausalMutation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||
|
A | 0.710 | CausalMutation | CLINVAR | Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. | 23406027 | 2013 |
|||
|
G | 0.710 | CausalMutation | CLINVAR | Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. | 23406027 | 2013 |
|||
|
G | 0.710 | CausalMutation | CLINVAR | Phase II trial of sorafenib in metastatic thyroid cancer. | 19255327 | 2009 |
|||
|
A | 0.710 | CausalMutation | CLINVAR | Phase II trial of sorafenib in metastatic thyroid cancer. | 19255327 | 2009 |
|||
|
G | 0.710 | CausalMutation | CLINVAR | Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. | 19773371 | 2009 |
|||
|
A | 0.710 | CausalMutation | CLINVAR | Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. | 19773371 | 2009 |
|||
|
G | 0.710 | CausalMutation | CLINVAR | Hyperactive Ras in developmental disorders and cancer. | 17384584 | 2007 |
|||
|
A | 0.710 | CausalMutation | CLINVAR | Hyperactive Ras in developmental disorders and cancer. | 17384584 | 2007 |